ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ORIN-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ORIN-1001 overview
ORIN-1001 is under development for the treatment of advanced solid tumors including relapsed refractory triple-negative breast cancer, ER+ HER2- breast cancer, MYC+ breast cancer, human epidermal growth factor receptor 2 positive breast cancer (HER22+ breast cancer). The drug candidate is a new chemical entity administered by oral route in the form of tablet. The drug candidate acts by targeting inositol requiring protein 1 (IRE1).
It was under development for treatment of hepatocellular carcinoma, prostate cancer, metastatic castration-resistant prostate cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, esophageal cancer, idiopathic pulmonary fibrosis, colorectal cancer and kidney cancer (renal cell cancer).
Shanghai Fosun Pharmaceutical (Group) overview
Shanghai Fosun Pharmaceutical (Group) (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co., Ltd., is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products are mainly applied in the treatment of metabolism and digestive system, cardiovascular system, blood system, central nervous system, anti-infection, anti-tumor, vaccine and raw material and intermediates. Fosun Pharma provides medical diagnostic products including a real-time PCR detector, human papillomavirus assay kit and biofosun microorganism identification and susceptibility analysis system. The company’s research and development unit concentrates on therapeutic areas of metabolism and digestive system, blood system, cardiovascular system and central nervous system. Fosun Pharma is headquartered in Shanghai, China.
For a complete picture of ORIN-1001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
